STUDY_ID	USUBJID	Visit Number	Visit Name	Visit Date	Treatment	HDL mg/dl	LDL mg/dl	TRIG mg/dl
TR171	OBS336-201_01	0	Baseline	2016-03-02	75 mg QD	51	204	408
TR171	OBS336-201_01	1	Week 1	2016-03-09	75 mg QD	52.1	208.4	416.8
TR171	OBS336-201_01	2	Week 2	2016-03-16	75 mg QD	53.2	212.8	425.6
TR171	OBS336-201_01	3	Week 3	2016-03-23	75 mg QD	54.3	217.2	434.4
TR171	OBS336-201_01	4	Week 4	2016-03-30	75 mg QD	55.4	221.6	443.2
TR171	OBS336-201_01	5	Week 5	2016-04-06	75 mg QD	56.5	226	452
TR171	OBS336-201_01	6	Week 6	2016-04-13		57.6	230.4	460.8
TR171	OBS336-201_02	0	Baseline	2016-02-29	Placebo	35	140	280
TR171	OBS336-201_02	1	Week 1	2016-03-07	Placebo	35.1	140.4	280.8
TR171	OBS336-201_02	2	Week 2	2016-03-14	Placebo	35.2	140.8	281.6
TR171	OBS336-201_02	3	Week 3	2016-03-21	Placebo	35.3	141.2	282.4
TR171	OBS336-201_02	4	Week 4	2016-03-28	Placebo	35.4	141.6	283.2
TR171	OBS336-201_02	5	Week 5	2016-04-04	Placebo	35.5	142	284
TR171	OBS336-201_02	6	Week 6	2016-04-11		35.6	142.4	284.8
TR171	OBS336-201_03	0	Baseline	2016-03-11	75 mg QD	62	248	496
TR171	OBS336-201_03	1	Week 1	2016-03-18	75 mg QD	62.1	248.4	496.8
TR171	OBS336-201_03	2	Week 2	2016-03-25	75 mg QD	62.2	248.8	497.6
TR171	OBS336-201_03	3	Week 3	2016-04-01	75 mg QD	62.3	249.2	498.4
TR171	OBS336-201_03	4	Week 4	2016-04-08	75 mg QD	62.4	249.6	499.2
TR171	OBS336-201_03	5	Week 5	2016-04-15	75 mg QD	62.5	250	500
TR171	OBS336-201_03	6	Week 6	2016-04-14		62.6	250.4	500.8
TR171	OBS336-201_04	0	Baseline	2016-03-09	Placebo	48	192	384
TR171	OBS336-201_04	1	Week 1	2016-03-16	Placebo	48.1	192.4	384.8
TR171	OBS336-201_04	2	Week 2	2016-03-23	Placebo	48.2	192.8	385.6
TR171	OBS336-201_04	3	Week 3	2016-03-30	Placebo	48.3	193.2	386.4
TR171	OBS336-201_04	4	Week 4	2016-04-06	Placebo	48.4	193.6	387.2
TR171	OBS336-201_04	5	Week 5	2016-04-12	Placebo	48.5	194	388
TR171	OBS336-201_04	6	Week 6	2016-04-19		48.6	194.4	388.8
TR171	OBS336-201_05	0	Baseline	2016-02-26	Placebo	29	116	232
TR171	OBS336-201_05	1	Week 1	2016-03-04	Placebo	29.1	116.4	232.8
TR171	OBS336-201_05	2	Week 2	2016-03-11	Placebo	29.2	116.8	233.6
TR171	OBS336-201_05	3	Week 3	2016-03-18	Placebo	29.3	117.2	234.4
TR171	OBS336-201_05	4	Week 4	2016-03-25	Placebo	29.4	117.6	235.2
TR171	OBS336-201_05	5	Week 5	2016-04-01	Placebo	29.5	118	236
TR171	OBS336-201_05	6	Week 6	2016-04-08		29.6	118.4	236.8
TR171	OBS336-201_06	0	Baseline	2016-03-01	Placebo	65	260	520
TR171	OBS336-201_06	1	Week 1	2016-03-08	Placebo	65.1	260.4	520.8
TR171	OBS336-201_06	2	Week 2	2016-03-15	Placebo	65.2	260.8	521.6
TR171	OBS336-201_06	3	Week 3	2016-03-22	Placebo	65.3	261.2	522.4
TR171	OBS336-201_06	4	Week 4	2016-03-29	Placebo	65.4	261.6	523.2
TR171	OBS336-201_06	5	Week 5	2016-04-05	Placebo	65.5	262	524
TR171	OBS336-201_06	6	Week 6	2016-04-12		65.6	262.4	524.8
TR171	OBS336-201_07	0	Baseline	2016-03-04	75 mg QD	40	160	320
TR171	OBS336-201_07	1	Week 1	2016-03-11	75 mg QD	40.1	160.4	320.8
TR171	OBS336-201_07	2	Week 2	2016-03-18	75 mg QD	40.2	160.8	321.6
TR171	OBS336-201_07	3	Week 3	2016-03-25	75 mg QD	40.3	161.2	322.4
TR171	OBS336-201_07	4	Week 4	2016-04-01	75 mg QD	40.4	161.6	323.2
TR171	OBS336-201_07	5	Week 5	2016-04-08	75 mg QD	40.5	162	324
TR171	OBS336-201_07	6	Week 6	2016-04-15		40.6	162.4	324.8
TR171	OBS336-201_08	0	Baseline	2016-03-07	75 mg QD	32	128	256
TR171	OBS336-201_08	1	Week 1	2016-03-14	75 mg QD	32.1	128.4	256.8
TR171	OBS336-201_08	2	Week 2	2016-03-22	75 mg QD	32.2	128.8	257.6
TR171	OBS336-201_08	3	Week 3	2016-03-29	75 mg QD	32.3	129.2	258.4
TR171	OBS336-201_08	4	Week 4	2016-04-05	75 mg QD	32.4	129.6	259.2
TR171	OBS336-201_08	5	Week 5	2016-04-12	75 mg QD	32.5	130	260
TR171	OBS336-201_08	6	Week 6	2016-04-19		32.6	130.4	260.8
